azelastine (astelin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Azelastine, a phthalazine derivative, is an antihistamine and mast cell stabilizer. Azelastine is oxidatively metabolized to the principal active metabolite, desmethylazelastine, by the cytochrome P450 enzyme system. It is indicated for the relief of the symptoms of seasonal allergic rhinitis and perennial allergic rhinitis. The most common adverse reactions are: pyrexia, dysgeusia, nasal discomfort, epistaxis, headache, sneezing, fatigue, somnolence, upper respiratory infection, cough, rhinalgia, vomiting, otitis media, contact dermatitis, and oropharyngeal pain. Concurrent use of Azelastine with alcohol or other central nervous system depressants should be avoided because reductions in alertness and impairment of central nervous system performance may occur.   NCATS

Chemistry

  • SMILES: CN1CCCC(CC1)N2N=C(Cc3ccc(Cl)cc3)c4ccccc4C2=O
  • InChIKey: MBUVEWMHONZEQD-UHFFFAOYSA-N
  • Mol. Mass: 381.91
  • ALogP: 4.3
  • ChEMBL Molecules:
    azelastine  
    azelastine hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0439 - $8.0000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( azelastine (astelin), fluticasone (cutivate) - other name: fluticasone nasal 50 mcg/inh nasal spray, azelastine nasal 140 mcg/inh nasal spray )

Alternative names

4-((4-chlorophenyl)methyl)-2- (hexahydro-1-methyl-1h-azepin-4-yl)-1(2h)- phthalazinone hcl | 4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1h-azepin-4-yl)-1-(2h)-phthalazinone | 4-(p-chlorobenzyl)-2-(n-methylperhydroazepinyl-(4))-1-(2h)-phthalazinone | a 5610 | a-5610 | afluon | allergodil | asta medica brand of azelastine hydrochloride | astelin | astepro | azelastina | azelastine | azelastine hcl | azelastine hydrochloride | azelastinum | azeptin | bayer brand of azelastine hydrochloride | corifina | dagra brand of azelastine hydrochloride | dymista | e-0659 | loxin | mann brand of azelastine hydrochloride | muro brand of azelastine | optilast | optivar | orion brand of azelastine hydrochloride | rhinolast | rhinolast allergy | sanfer brand of azelastine hydrochloride | viatris brand of azelastine hydrochloride | vividrin akut azelastin | w-2979m | wallace brand of azelastine hydrochloride

Organizations (73)

Research & Development (53)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (25)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (4)


 

Conjunctivitis, Allergic

Rhinitis, Allergic, Perennial (approved 1996)

Rhinitis, Allergic, Seasonal

Rhinitis, Vasomotor

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Allergy and Immunology (Phase 4)

Asthma (Phase 4)

COVID-19 (Phase 4)

Hypersensitivity (Phase 4)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Perennial (Phase 4)

Rhinitis, Allergic, Seasonal ()

Rhinitis, Vasomotor (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 56
  • # of Trial Organizations: 53

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue